re,
Cephalon does not intend to update publicly any forward-looking statement,
except as required by law. The Private Securities Litigation Reform Act of
1995 permits this discussion.
This press release and/or the financial results attached to this press
release include "Adjusted Net Income," "Basic Adjusted Income per Common
Share," "Basic Adjusted Income per Common Share Guidance," and "Diluted
Adjusted Income Per Common Share," amounts that are considered "non-GAAP
financial measures" under SEC rules. As required, we have provided
reconciliations of these measures. Additional required information is
located in the Form 8-K furnished to the SEC in connection with this press
release.
CEPHALON, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2007 2006 2007 2006
REVENUES:
Sales $428,729 $470,513 $1,287,802 $1,246,825
Other revenues 9,692 11,820 34,865 32,562
438,421 482,333 1,322,667 1,279,387
COSTS AND EXPENSES:
Cost of sales 82,258 83,160 251,970 250,613
Research and development 93,527 86,439 274,078 294,899
Selling, general and
administrative 186,456 161,108 527,962 470,158
Settlement reserve 369,000 - 425,000 -
Impairment charge - - - 12,417
731,241 330,707 1,479,010 1,028,087
INCOME (LOSS) FROM OPERATIONS (292,820) 15
'/>"/>
SOURCE Cephalon, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related biology technology :1.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain2.
Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant3.
Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA4.
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia5.
Cephalon Quarterly Conference Call Invitation6.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients7.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 268.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering9.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.10.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets11.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results